Chugai (Formerly Chugai Pharmaceutical Co. Ltd.)

9 articles about Chugai (Formerly Chugai Pharmaceutical Co. Ltd.)

• 

  Roche’s IL-6 Blocker Clears Phase III Bar, Still Falls Short of Expectations

  3/22/2024

  Despite meeting its primary endpoint in a late-stage generalized myasthenia gravis trial, Roche and Chugai Pharmaceutical’s Enspryng did not demonstrate clinical benefit as expected, the companies announced Thursday.
• 

  British Firm Identifies Seven Late-Stage Drugs with Blockbuster Potential

  1/11/2022

  U.K.-based Clarivate Plc has identified seven late-stage assets or recently-approved drugs that could hit the billion-dollar per year mark within five years.

• Atea Pharmaceuticals Announces Chugai In-License of AT-527 from Roche for the Treatment of COVID-19 in Japan

  2/19/2021

  Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that Chugai Pharmaceutical Co., Ltd. has in-licensed the rights for AT-527 for the treatment of COVID-19 in Japan from Roche.

• New Interim Results from Phase IIIb Study Reinforce the Long-Term Safety Profile of Chugai’s Hemlibra in Hemophilia A

  7/13/2020

  Chugai Pharmaceutical Co., Ltd. announced that the second interim analysis results from the phase IIIb STASEY study reinforce the safety profile of Hemlibra® characterized in the phase III HAVEN studies

• Thermo Fisher Scientific Signs Companion Diagnostic Agreement with Chugai Pharmaceutical

  7/8/2020

  Agreement aims to expedite local biomarker testing of NSCLC patients eligible for entrectinib in Japan

• Chugai Implements Genedata Profiler to Accelerate Data-driven Biomarker Discovery

  3/10/2020

  Genedata Profiler used for biomarker discovery and validation projects in support of Chugai’s early proof of concept research initiatives

• Foundation Medicine and Chugai Announce Partnership with National Cancer Center for the Use of FoundationOne®Liquid in the Third Stage of SCRUM-Japan

  2/13/2020

  SCRUM-Japan aims to apply blood-based genomic insights to inform and accelerate the development of precision medicine approaches for patients with advanced cancers

• Results from Phase III SAkuraSky Study for Chugai’s Satralizumab in Neuromyelitis Optica Spectrum Disorder Published in The New England Journal of Medicine Online

  11/29/2019

  Satralizumab added to baseline immunosuppressant therapy significantly reduced risk of relapse in patients with neuromyelitis optica spectrum disorder (NMOSD).

• Chugai Renews License to EpiVax's ISPRI In Silico Toolkit for Immunogenicity Assessment

  10/22/2019

  ugai Pharmaceutical Co., Ltd., a member of the Roche Group, will extend the company's licensed access to the Immunogenicity Screening and Protein Reengineering Interface toolkit developed by EpiVax, Inc.